So now that they have a partner for distribution how does this affect MSB
1. Exposure to patients provides trial opportunities -> lower cost trials -> lower cash burn
2. Exposure to practitioners -> no need for salesforce -> lower cash burn
3. Extra $110m USD not tied to just Rex-L but free deploy funds for Rem-L confirmatory trials
4. Extra exposure to other ortho indications beyond backpain -> increased market opportunities
So now that they have a partner for distribution how does this...
-
- There are more pages in this discussion • 319 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 11599 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 17835 | 5 |
View Market Depth
| Last trade - 09.57am 20/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable